- |||||||||| Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Updated results from a phase II study of penpulimab plus anlotinib as first-line therapy in metastatic urothelial cancer (mUC). (Hall A; Poster Bd #: 268) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1738; Background: Cisplatin-based chemotherapy is the standard-of-care systemic treatment for mUC patients with good physical status and organ function, which has shown a response in more than 40% of patients, with mOS approximately 15 months. Penpulimab plus anlotinib demonstrated promising antitumor activity and manageable safety profile with no new safety signal in mUC.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data, Journal, Real-world evidence, Real-world, Metastases: Anlotinib for Metastatic Progressed Pheochromocytoma and Paraganglioma: A Retrospective Study of Real-World Data. (Pubmed Central) - Apr 23, 2024 Anlotinib monotherapy or in combination with radionuclide therapies shows promising efficacy and safety for the treatment of LA/M PCC and PGL. Multi-tyrosine kinase inhibitors might represent a novel therapeutic strategy for patients with PPGL; however, large-scale prospective randomized, blinded, controlled clinical research studies are required.
- |||||||||| Tyvyt (sintilimab) / Innovent Biologics, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion, Trial primary completion date, Metastases: Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) (clinicaltrials.gov) - Apr 23, 2024 P2, N=30, Completed, Multi-tyrosine kinase inhibitors might represent a novel therapeutic strategy for patients with PPGL; however, large-scale prospective randomized, blinded, controlled clinical research studies are required. Recruiting --> Completed | Trial primary completion date: Dec 2023 --> Sep 2023
- |||||||||| Mekinist (trametinib) / Novartis, BeiGene, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion, Trial completion date, Trial primary completion date: Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients (clinicaltrials.gov) - Apr 22, 2024 P1, N=33, Completed, Not yet recruiting --> Recruiting | Initiation date: Apr 2024 --> Jan 2024 Recruiting --> Completed | Trial completion date: Aug 2023 --> Mar 2024 | Trial primary completion date: Jan 2023 --> Jul 2023
- |||||||||| Kaitanni (cadonilimab) / Akesobio, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date: Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer (clinicaltrials.gov) - Apr 18, 2024 P2, N=35, Recruiting, Patients with clinical stage II/III TNBC were treated with 5 cycles of anlotinib (12 Trial completion date: Mar 2025 --> Feb 2027 | Trial primary completion date: Oct 2024 --> Nov 2025
- |||||||||| Opdivo (nivolumab) / BMS, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date, Combination therapy: Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors (clinicaltrials.gov) - Apr 17, 2024 P1/2, N=56, Active, not recruiting, Trial completion date: Mar 2025 --> Feb 2027 | Trial primary completion date: Oct 2024 --> Nov 2025 Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
|